Skip to main content
Equibles
ADIL logo

ADIL · Adial Pharmaceuticals, Inc.

Track ADIL — free Ask ALVIS about ADIL
$3.34 +0.05 (+1.52%) At close · Jul 31
Going-concern doubt — flagged May 8, 2026

Substantial doubt about the company's ability to continue as a going concern.

“the Company does not believe that the existing cash and cash equivalents are sufficient to fund operations for the next twelve months following the filing of these unaudited condensed financial statements. During 2026, the Company received net proceeds of approximately $0.3 million from equity issuances. However, the Company will require additional capital to continue operations and development of AD04. These factors raise substantial doubt about the Company’s ability to continue as a going concern.”
View the 10-Q filed May 8, 2026
Market Cap
$7.16M
Shares
2.14M

Price & Indicators

Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$3.34 Open$3.30 Day$3.20–3.38 52W$1.31–12.00 Avg vol 30d56K Short int244K · 11.4% float · 5.3d Short vol37% Last earningsNov 15, 2022 DataJan 2020–Jul 2026 Filing10-Q · May 8

Up next

FQ3-26 quarter ends
~Sep 30, 2026 Est
Latest filing: 10-Q
filed May 8, 2026

Equibles Rating

blended score · not investment advice
Overall
Neutral
SellHoldBuy
Technical Neutral Momentum Strong Sentiment Bullish Fundamentals Strong Quant / Vol Very High
Market backdrop VIX 16 · calm Equity put/call 0.61
Technical
price trend
Neutral
50 / 200-day cross No cross
Price vs 200-day avg −20%
below
Price vs 50-day avg +26%
above
RSI (14) 73
overbought
MACD trend Positive
52-week position 19%
mid-range
Volume (OBV) Confirms
volume backs price
Momentum
relative strength
Strong
1-month return +15%
trailing
6-month return +7%
trailing
YTD return −39%
this year
Relative strength −1%
vs S&P · 6-mo
Sentiment
smart money
Bullish
Trend (MA cross) No cross
50d $3 › 200d $4 — 200d above 50d
Institutional flow Accumulating
4 of 15 funds reported for Jun 30 · net +8.0K sh shares · +1 new
Insider flow Accumulating
Net +$106.3K over 90 days · 0% sells
Short interest Rising
11.37% of float · ▲ +5.5% MoM · 5.3 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
15 holders — near 3-yr high, broad support
Squeeze score 82
high risk · 0–100
Fundamentals
Strong
EPS growth +82%
Y/Y
Free cash flow $-6.6M
Balance sheet $5.9M
net cash
Quant / Vol
risk profile
Very High
Volatility 87%
annualized · 1-yr
Max drawdown −88%
past year
ATR 7.0%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Neutral
2 · 3 · 2
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
−20% Bearish
Price vs 50-day avg
+26% Bullish
RSI (14)
73 Bearish
MACD trend
Positive Bullish
52-week position
19% Neutral
Volume (OBV)
Confirms Neutral
Market signals — smart money & positioning
Bullish · 3 of 6
Trend (MA cross) No cross
50d $3 › 200d $4 — 200d above 50d
Institutional flow Accumulating
4 of 15 funds reported for Jun 30 · net +8.0K sh shares · +1 new
Insider flow Accumulating
Net +$106.3K over 90 days · 0% sells
Short interest Rising
11.37% of float · ▲ +5.5% MoM · 5.3 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
15 holders — near 3-yr high, broad support
Price context
position in its 52-week range
52-wk low $1 Now $3 · 19% 52-wk high $12
vs 200-day avg -20% vs 50-day avg +26%

Illustrative technical + ownership context — a signal mix, not investment advice.

Versus peers

Biotechnology — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
ADIL
Adial Pharmaceuticals, Inc.
this stock
$7.16M -39.3% — — 11.4%
ONC
BeOne Medicines Ltd.
 $456.72B +4.0% +22179.2% 929.4 0.1%
VRTX
Vertex Pharmaceuticals Inc / Ma
 $121.09B +5.2% +46.2% 28.3 2.0%
REGN
Regeneron Pharmaceuticals, Inc.
 $78.52B -1.1% +20.8% 18.9 3.4%
ARGX
Argenx SE
 $53.42B +1.5% — — 2.5%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Accumulating
Holders
16
% held
2.0%
Reported
4 of 15
Top holder
GEODE CAPITAL MANAGEMENT,…
Held Float
View
Held by Funds
Fund positions
4
View
Short & Settlement
Short Interest Rising
Shares short
243.6K
Days to cover
5.3d
Change
+12.6K sh
View
Short Volume
Short vol %
37%
As of
Jul 31, 2026
Short Total
View
Fails to Deliver
FTD shares
1.6K
Value
$4.3K
As of
Jul 13, 2026
View
Off-Exchange
Off-exchange %
60.7%
Week of
May 4, 2026
Off-exch Lit
View
Smart Money
Insider Trades Net buying
Net (90d)
+$106.3K
Buyers / Sellers
1 / 0
Buyers Sellers
View
Financials
Financials
Net income (FY)
$-8.0M
EPS diluted
$-11.93
View
Buybacks
Authorized
shares 26.7K
Remaining
shares 13.3K
Spent Remaining
View
Filings
SEC Filings
Latest
Investor Event Transcript
Filed
Jun 30, 2026
This year
12
View
Exempt Offerings
Offering
$4.3M
Filed
Dec 3, 2025
View
Earnings & Events
Earnings Calls
Last call
Jun 11, 2026
View

Performance

5D 20D 120D MTD YTD
ADIL +20.1% +15.2% +7.1% +30.5% -39.3%
SPY +1.1% +0.3% +8.2% +0.0% +9.6%
vs SPY +19.0% +14.9% -1.1% +30.4% -48.8%

Capital returns

Buyback program · as of Dec 31, 2023
Authorized
shares 26,665
Spent (derived)
shares 13,330
Remaining
shares 13,335
Spent Remaining

Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.

Key facts CIK 1513525 CUSIP 00688A304 13F (30d) 29 filings 4 filers Visit website Investor relations

Report a Problem

Category
Description
Email (optional, for follow-up)